In Brief: Island Glow
This article was originally published in The Tan Sheet
Executive Summary
Island Glow: FDA warning letter sent to sun tanning products' maker Centre Manufacturing for misbranding. Dated Jan. 8, the letter states that the St. Paul, Minn.-based company's Island Glow and private label suntanning products are unapproved new drugs based on claims such as, "Speeds up the tanning process" with tyrosine. FDA "is not aware of any data demonstrating that tyrosine or its derivatives are effective in stimulating the production of melanin," the letter states. In addition, U.S. material time/material extent marketing data are not available on the products, and the ingredients in the items are not GRAS/E, the letter states. The products also are misbranded because the labels "fails to bear adequate directions for use for the conditions that are offered"...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning